|
WO2021073643A1
|
|
Drug for treating non-alcoholic steatohepatitis
|
|
WO2021058021A1
|
|
Drug combination containing tlr7 agonist
|
|
WO2021058001A1
|
|
Crystal form of five-membered n heterocyclic compound, and application thereof
|
|
WO2021058002A1
|
|
Crystalline form of capsid protein assembly inhibitor containing n hetero five-membered ring, and application thereof
|
|
WO2021043200A1
|
|
Method for preparing quinazoline derivative and crystallization thereof
|
|
WO2021018310A1
|
|
Aminopyridine derivatives for treatment of non-small cell lung cancer
|
|
US2020352932A1
|
|
Quinoline derivative for treatment of nasopharyngeal carcinoma
|
|
CN112274511A
|
|
Quinoline derivatives for the treatment of graft versus host disease
|
|
WO2021008441A1
|
|
Btk inhibitor containing 5-azaspiroheptane
|
|
CN112209933A
|
|
BTK inhibitors containing 4-azaspiroheptane
|
|
CN112209934A
|
|
BTK inhibitors containing azaspiroheptanes
|
|
US2020316053A1
|
|
Application of novel tyrosine kinase inhibitor, anlotinib, in osteosarcoma and chondrosarcoma
|
|
CN112121048A
|
|
Quinolines for the combined treatment of esophageal cancer
|
|
CN112043832A
|
|
Quinolines for the combined treatment of gastric cancer
|
|
CN112043702A
|
|
Quinolines for the combined treatment of colorectal cancer
|
|
CN112043831A
|
|
Quinolines for use in the combined treatment of breast cancer
|
|
WO2020239107A1
|
|
Tetracyclic compounds as cdc7 inhibitors
|
|
CN112007026A
|
|
Antibacterial composition containing abamectin and meropenem and application thereof
|
|
WO2020233723A1
|
|
Quinoline derivatives for treatment of head and neck cancer
|
|
WO2020238785A1
|
|
Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective bcl-2 inhibitor
|
